• LOGIN
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publication
  • Projects
  • Funding
  • Research Data
  • Organizations
  • Researchers
  • LOGIN
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Impella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis.
 

Impella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis.

Options
  • Details
BORIS DOI
10.48350/163223
Date of Publication
April 2021
Publication Type
Article
Division/Institute

Universitätsklinik fü...

Author
Wernly, Bernhard
Karami, Mina
Engström, Annemarie E
Windecker, Stephan
Universitätsklinik für Kardiologie
Hunziker Munsch, Lukas Christoph
Universitätsklinik für Kardiologie
Lüscher, Thomas F
Henriques, Jose P
Ferrari, Markus W
Binnebößel, Stephan
Masyuk, Maryna
Niederseer, David
Abel, Peter
Fuernau, Georg
Franz, Marcus
Kelm, Malte
Busch, Mathias C
Felix, Stephan B
Thiele, Holger
Lauten, Alexander
Jung, Christian
Subject(s)

600 - Technology::610...

Series
ESC Heart Failure
ISSN or ISBN (if monograph)
2055-5822
Publisher
Wiley
Language
English
Publisher DOI
10.1002/ehf2.13200
PubMed ID
33560591
Uncontrolled Keywords

Cardiogenic shock ECM...

Description
AIMS

The mortality in cardiogenic shock (CS) is high. The role of specific mechanical circulatory support (MCS) systems is unclear. We aimed to compare patients receiving Impella versus ECLS (extracorporal life support) with regard to baseline characteristics, feasibility, and outcomes in CS.

METHODS AND RESULTS

This is a retrospective cohort study including CS patients over 18 years with a complete follow-up of the primary endpoint and available baseline lactate level, receiving haemodynamic support either by Impella 2.5 or ECLS from two European registries. The decision for device implementation was made at the discretion of the treating physician. The primary endpoint of this study was all-cause mortality at 30 days. A propensity score for the use of Impella was calculated, and multivariable logistic regression was used to obtain adjusted odds ratios (aOR). In total, 149 patients were included, receiving either Impella (n = 73) or ECLS (n = 76) for CS. The feasibility of device implantation was high (87%) and similar (aOR: 3.14; 95% CI: 0.18-56.50; P = 0.41) with both systems. The rates of vascular injuries (aOR: 0.95; 95% CI: 0.10-3.50; P = 0.56) and bleedings requiring transfusions (aOR: 0.44; 95% CI: 0.09-2.10; P = 0.29) were similar in ECLS patients and Impella patients. The use of Impella or ECLS was not associated with increased odds of mortality (aOR: 4.19; 95% CI: 0.53-33.25; P = 0.17), after correction for propensity score and baseline lactate level. Baseline lactate level was independently associated with increased odds of 30 day mortality (per mmol/L increase; OR: 1.29; 95% CI: 1.14-1.45; P < 0.001).

CONCLUSIONS

In CS patients, the adjusted mortality rates of both ECLS and Impella were high and similar. The baseline lactate level was a potent predictor of mortality and could play a role in patient selection for therapy in future studies. In patients with profound CS, the type of device is likely to be less important compared with other parameters including non-cardiac and neurological factors.
Handle
https://boris-portal.unibe.ch/handle/20.500.12422/59045
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
Impella_versus_extracorporal.pdftextAdobe PDF230.55 KBAttribution-NonCommercial (CC BY-NC 4.0)publishedOpen
BORIS Portal
Bern Open Repository and Information System
Build: 360c85 [14.04. 8:05]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo